AstraZeneca Annual Report and Form 20-F Information 2008

Notes to the Financial Statements (Group)

• 16 Financial instruments
• 17 Trade and other payables
• 18 Provisions for liabilities and charges
• 19 Capital and reserves
• 20 Share capital of parent company

20 Share capital of parent company

	Authorised	Allotted, called-up and fully paid
	2008 $m	2008 $m	2007 $m	2006 $m
Issued Ordinary Shares ($0.25 each)	362	362	364	383
Unissued Ordinary Shares ($0.25 each)	238	–	–	–
Redeemable Preference Shares (£1 each – £50,000)	–	–	–	–
	600	362	364	383

The total authorised number of Ordinary Shares at 31 December 2008 was 2,400,000,000, of which 1,447,481,548 Ordinary Shares were in issue.

The Redeemable Preference Shares carry limited class voting rights and no dividend rights. This class of shares is capable of redemption at par at the option of the Company on the giving of seven days’ written notice to the registered holder of the shares.

The movements in the number of shares during the year can be summarised as follows:

No. of shares (million)
	2008	2007
At 1 January	1,457	1,532
Issues of shares	4	5
Re-purchase of shares	(14)	(80)
At 31 December	1,447	1,457

Share re-purchases

During the year the Company re-purchased, and subsequently cancelled, 13,597,940 Ordinary Shares at an average price of 2397 pence per share. The total consideration, including expenses, was $610m. The consideration has been charged against retained earnings.

Share schemes

A total of 4,078,635 Ordinary Shares were issued during the year in respect of share schemes. Details of movements in the number of Ordinary Shares under option are shown in Note 24; details of options granted to Directors are shown in the Directors’ Remuneration Report.

Shares held by subsidiaries

No shares in the Company were held by subsidiaries in any year.

Back to the top